This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Surgical Oncology  • Liver Transplantation  • Hepatobiliary Surgery  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Expanding Special Priority to Include Stage III Disease

Jeremy Goodman, MD; Sean C. Glasgow, MD; Mark Schnitzler, PhD; Jeffrey A. Lowell, MD; Surendra Shenoy, MD, PhD; Martin D. Jendrisak, MD; Niraj Desai, MD; Mauricio Lisker-Melman, MD; Jeffrey Crippin, MD; William C. Chapman, MD

Arch Surg. 2005;140:459-464.

Hypothesis  After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects.

Design  Retrospective review of prospectively collected database.

Setting  University hospital.

Patients  Fifty-one adults with HCC and 153 matched adults without HCC who underwent orthotopic liver transplantation.

Main Outcome Measures  One-, 3-, and 5-year survivals for all groups. After matching for year of transplantation, age, sex, and underlying liver disease, long-term survival was compared between groups. Rates of recurrence were also measured in the HCC groups.

Results  From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC. One hundred fifty-one patients without HCC who underwent transplantation were selected as controls. Patient demographic features were similar between case-control groups. The overall 5-year survival trend was worse for patients with HCC vs their matched controls (48% vs 65%; P = .07); however, this survival disadvantage was eliminated when patients with stages I through III HCC were combined and compared with their matched controls (59% vs 63%; P = .96). Survival of patients with stage III disease was comparable to that of matched controls (65% vs 59%; P = .44).

Conclusions  For patients with stages I through III disease, long-term survival is comparable to that of matched controls, and only patients with stage IV disease experience poorer survival. Consideration should be given to granting exception points to patients with stage III disease.

Author Affiliations: Section of Abdominal Transplantation, Department of Surgery (Drs Goodman, Glasgow, Schnitzler, Lowell, Shenoy, Jendrisak, Desai, and Chapman), and Division of Gastroenterology, Department of Medicine (Drs Lisker-Melman and Crippin), Washington University, and Siteman Cancer Center (Drs Lisker-Melman and Chapman), St Louis, Mo.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Stage IVA Hepatocellular Carcinoma--Invited Critique
Chapman
Arch Surg 2008;143:543-543.
FULL TEXT